Project Grant K01HL174889
Award Date
9/1/24
Completion Date
8/31/29
Dollars Obligated
$324K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Charlottesville, VA, USA
Similar Awards
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under CFDA 93.837 - Cardiovascular Diseases Research, provides $1,543,226 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to conduct a randomized controlled trial assessing the effects of SGLT2 inhibitors on coronary flow reserve and epicardial adipose tissue among women living with HIV. The 5-year project, which commenced on September 1, 2024, aims to identify...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) will provide $131,085 to The Leland Stanford Junior University to elucidate the cardiac-protective mechanisms of sodium-glucose cotransporter-2 (SGLT2) inhibitors, a class of drugs initially developed to treat diabetes. The research aims to leverage human induced pluripotent stem cell-derived cardiovascular cells, single-cell RNA sequencing, metabolomics, and protein...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $1,383,228 to the University of South Florida to investigate how post-translational modifications of the calcium/calmodulin-dependent protein kinase II (CaMKII) enzyme impact endothelial function and coronary microvascular dysfunction in diabetes. The research aims to define the mechanisms by which excessive CaMKII phosphorylation,...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will fund research to generate human induced pluripotent stem cell (iPSC) models of type 2 diabetic cardiomyopathy (T2DCM) and assess the metabolic mechanisms and protective effects of sodium-glucose cotransporter-2 (SGLT2) inhibitors. The total award is $511,864 with a project period from Sep 6, 2024 to Mar 31, 2026. The research will be...
The federal Project Grant award of $100,050.00 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support research to investigate the potential role of cardiometabolic drugs, such as glucagon-like peptide 1 receptor agonists (GLP1-RA) and sodium-glucose cotransporter-2 inhibitors (SGLT2I), as well as the repurposing of metformin and bariatric surgery, in reducing the burden of atrial fibrillation (AF). The research...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $2,158,878 to the Rector & Visitors of the University of Virginia (UVA) to advance research on mitigating intimal hyperplasia (IH), a condition that can re-narrow arteries after angioplasty procedures. The key objectives are to: 1) Resolve the endothelial cell-specific role of the enzyme ALDH1A3 in IH pathophysiology and its...
This federal Project Grant award of $1,127,798 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research to understand the role of macrophages in preserving cardiovascular health and their contributions to cardiovascular disease (CVD). The overarching goal is to identify new therapeutic targets for CVD in both female and male patients. The research will use advanced single cell imaging and omics techniques to characterize harmful...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $2,352,138 Project Grant under CFDA 93.837 - Cardiovascular Diseases Research to the Rector & Visitors of the University of Virginia. The grant aims to model and experimentally validate cell-specific signaling networks involving the low-density lipoprotein receptor-related protein 1 (LRP1) in acute myocardial infarction (AMI). The research will focus on understanding how early cardiomyocyte LRP1 signaling enhances cell...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $455,826 to conduct a double-blind, randomized, placebo-controlled trial to determine the effects of chronic sildenafil administration on vascular remodeling during left ventricular assist device (LVAD) support. The study aims to assess the impact of sildenafil, a phosphodiesterase-5 inhibitor, on aortic stiffness, carotid...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $506,665.57 Project Grant under CFDA 93.837 - Cardiovascular Diseases Research to The University of Texas Southwestern Medical Center (UT Southwestern) to conduct research on the role of the TSPAN14 gene in coronary artery disease (CAD) pathogenesis. The project aims to determine how genetic variations in the 10q23 enhancer region regulate TSPAN14 expression in vascular endothelial cells and monocytes, and elucidate the...